In August 2024, the life sciences M&A landscape witnessed significant activity with an inclination towards smaller deals rather than blockbuster transactions. Prominent deals included AI and drug discovery, underscoring the growing influence of artificial intelligence in healthcare. The notable merger between Recursion and Exscentia stands out, with the combined entity boasting an $850 million balance sheet value and $100 million in synergies. Other key transactions featured Otsuka Pharmaceutical acquiring Jnana Therapeutics, Merck purchasing Curon Biopharmaceutical’s therapy, and Johnson & Johnson acquiring V-Wave. Mindwaves Ventures sold Maia to DrDoctor, indicating a deeper integration of mental health into healthcare support. Additionally, Zurich-based Redalpine closed a $200 million fundraising round and opened a new office in London, signaling growing interest in UK tech and life sciences innovation.
Life Sciences, Artificial Intelligence, Healthcare,Global, United Kingdom
https://mergersacquisitions.einnews.com/article/740702843/hUkSR85V8a6o5nxc?ref=rss&ecode=Q1vNcweEggLWKz7L